MatthewBarthMD

Pediatric Hematology & Oncology • Buffalo, NY

Pediatric Hematologic Oncology, Pediatric Neuro-Oncology

Clinical Associate Professor, Jacobs School of Medicine and Biomedical Sciences at University at Buffalo Pediatric Transplant and Cellular Therapy Co-Director of Pediatric Neuro-Oncology Director of Pediatric Neurofibromatosis Program

Join to view full profile

Dr. Barth is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Barth's full profile

Already have an account?

Office
818 Ellicott St
Buffalo, NY 14203
Phone+1 716-845-2333

Fax+1 716-845-8003

Summary

Dr. Matthew Barth is a pediatric hematologist/oncologist in Buffalo, NY and is affiliated with John R Oishei Children's Hospital and Roswell Park Comprehensive Cancer Center. He received his medical degree from SUNY Upstate Medical University and has been in practice 12 years. He is experienced in lymphoma, personalized medicine, leukemia, stem cell transplant, cellular therapy and neuro oncology.

Education & Training

University at BuffaloFellowship, Pediatric Hematology/Oncology, 2008 - 2011
University at BuffaloResidency, Pediatrics, 2005 - 2008
SUNY Upstate Medical UniversityClass of 2005

Certifications & Licensure

NY State Medical License 2008 - 2025
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

Young Investigator Award International Society of Paediatric Oncology, 2016
Henry C. and Bertha H. Buswell Fellowship University at Buffalo, 2011-2014
Travel Award 11th International Conference on Malignant Lymphoma, 2011
Thomas F. Frawley Resident Research Fellowship University at Buffalo, 2011
Join now to see all

Clinical Trials

Treatment for Advanced B-Cell Lymphoma Start of enrollment: 2013 Jan 01
Completed
Phase 2
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL Start of enrollment: 2015 Aug 21
Recruiting
Phase 2

Publications & Presentations

PubMed

130 citations
Genomewide linkage analysis of quantitative spirometric phenotypes in severe early-onset chronic obstructive pulmonary disease.
Edwin K. Silverman, Lyle J. Palmer, Jonathan D. Mosley, Matthew J. Barth, Jody M. Senter
American Journal of Human Genetics. 2002-05-01
24 citations
Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo
Natalie M Czuczman, Matthew J. Barth, Juan Gu, Vishala T. Neppalli, Cory Mavis
Blood. 2016-03-03
7 citations
Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-risk Leukemias: A Report from the LEAP Consortium
Yana Pikman, Sarah K. Tasian, Maria Luisa Sulis, Kristen E. Stevenson, Traci M. Blonquist
Cancer Discovery. 2021-06-01

Abstracts/Posters

Polatuzumab Vedotin, an Antibody-Drug Conjugate Targeting CD79b, Is a Highly Active Agent Against Burkitt Lymphoma and Primary Mediastinal B-Cell Lymphoma
Matthew J. Barth, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
BCL-Xl Expression Is Druggable Biomarker Associated with a Poor Clinical Outcome in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Matthew J. Barth, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019